Inclisiran 300 mg Suppliers & Bulk Manufacturers

Available Forms: injection (prefilled syringe)

Available Strengths: 300 mg

Reference Brands: Leqvio (USA/EU)

Category: Heart Disorder

Inclisiran is a small interfering RNA (siRNA) therapy that works by reducing the production of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in the liver, which in turn increases the number of LDL receptors and helps remove more LDL cholesterol from the blood. It is used to lower LDL cholesterol in patients with high cholesterol (hypercholesterolemia) or atherosclerotic cardiovascular disease, especially when statins alone are insufficient or not tolerated.

Product Description:

Inclisiran is a small interfering RNA that silences the gene for PCSK9 in liver cells. PCSK9 promotes breakdown of LDL receptors, so less PCSK9 means more receptors on the liver surface and more LDL cholesterol cleared from the blood. A sugar tag directs the molecule specifically to liver cells, and because the RNA-induced silencing complex persists inside the cell, one injection works for months.

It is given subcutaneously, with a second dose at three months and then every six months, which makes it the only lipid-lowering therapy administered twice a year — adherence is the main argument for it. It lowers LDL cholesterol by about half when added to a statin, and is used in patients whose LDL remains high on maximum tolerated statin therapy, and in familial hypercholesterolaemia. Injection site reactions are the main adverse effect. Cardiovascular outcome trials are still reporting, so the clinical benefit is inferred from LDL reduction.

Sourcing notes. Originator product, on patent, no generic. Because it is given by a health professional twice a year, several markets fund it through primary care programmes, which shapes volume. Cold chain is not required for storage at room temperature, but the licensed conditions should be confirmed per market.